HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.

Abstract
Low-molecular-weight heparin has the potential for the treatment of ulcerative colitis, and targeted drug delivery to the colon is important for topical treatment of this disease, so low-molecular-weight heparin oral colon-specific delivery capsule was prepared, and the in vitro and in vivo drug release behavior was investigated. The macroscopical and histological scoring systems, wet colon mass index and myeloperoxidase activity were assessed to evaluate the efficacy of the capsule after administered orally to experimental colitis mice. Serum levels, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and a link factor of blood coagulation and inflammation factor Xa (FXa) were assayed by enzyme-linked immunosorbent assay. The expression of Musashi-1 (as an intestinal stem cell marker) in the colons was assessed by immunohistochemical analysis. The in vitro and in vivo drug release studies clearly indicated that the specific coated capsules were capable of protecting low-molecular-weight heparin from releasing in stomach and small intestine, while specifically delivering at colon. The oral colon-specific delivery capsule of low-molecular-weight heparin could attenuate macroscopic and histological features of colitis. The results showed that low-molecular-weight heparin oral colon-specific delivery capsule significantly decreased the serum levels of TNF-α, IL-6 as well as FXa, while increased the expression of Musashi-1 in colon compared with acetic acid-induced ulcerative colitis model group. The results showed that low-molecular-weight heparin oral colon-specific delivery capsule had the potential for treatment of inflammatory bowel disease.
AuthorsJun-Yong Luo, Yan Zhong, Ji-Chao Cao, Hui-Fei Cui
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 65 Issue 2 Pg. 111-7 (Mar 2011) ISSN: 1950-6007 [Electronic] France
PMID21227626 (Publication Type: Journal Article)
CopyrightCopyright © 2010 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Anticoagulants
  • Interleukin-6
  • Msi1h protein, mouse
  • Nerve Tissue Proteins
  • RNA-Binding Proteins
  • Tumor Necrosis Factor-alpha
  • Factor Xa
  • Dalteparin
Topics
  • Administration, Oral
  • Animals
  • Anticoagulants (administration & dosage, pharmacology)
  • Colitis, Ulcerative (drug therapy, pathology)
  • Colon (metabolism)
  • Dalteparin (administration & dosage, pharmacology)
  • Disease Models, Animal
  • Drug Delivery Systems
  • Enzyme-Linked Immunosorbent Assay
  • Factor Xa (metabolism)
  • Female
  • Interleukin-6 (blood)
  • Male
  • Mice
  • Nerve Tissue Proteins (metabolism)
  • RNA-Binding Proteins (metabolism)
  • Tumor Necrosis Factor-alpha (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: